Prosecution Insights
Last updated: October 02, 2026

Examiner: ABUZEINEH, HANAN ISAM

Tech Center 1700 • Art Units: 1600 1633 1651 1732

This examiner grants 53% of resolved cases

Analysis

Hanan Isam Abuzeineh is an examiner in Tech Center 1700 and Art Unit 1600 with 77 resolved cases. The examiner's allowance rate stands at 54.5 percent. The median days to allowance for these cases is 1450.

A significant data point is the interview lift of 52.9 percent. This figure indicates that interviews are highly effective when compared to the 54.5 percent base rate. The 1450 days to allowance suggests a relatively long prosecution cycle for successful applications.

With 77 resolved cases, the examiner's patterns are well-defined. The 52.9 percent interview lift is a critical factor for practitioners to consider when navigating Art Unit 1600. The allowance rate combined with the median timeline provides a framework for managing client expectations regarding both the probability and duration of a successful outcome in this specific field of technology.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

53.2%
Allow Rate
-11.8% vs TC avg
104
Total Applications
+54.3%
Interview Lift
1444
Avg Prosecution Days
Based on 79 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
17.4%
§102 Novelty
46.0%
§103 Obviousness
27.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18717658 Indicator Clearance Monitoring in Machine Perfusion of an Organ Non-Final OA The Medical College of Wisconsin, Inc.
17997575 MULTISPECIFIC ANTI-FLT3 CHIMERIC ANTIGEN RECEPTORS Final Rejection The Regents of the University of Colorado, A Body Corporate
17782071 GENETICALLY ENGINEERED DOUBLE NEGATIVE T CELLS AS AN ADOPTIVE CELLULAR THERAPY Non-Final OA University Health Network
18559778 SYNTHETIC RECEPTORS Non-Final OA UCL BUSINESS LTD
17797551 GENETICALLY MODIFIED MEGAKARYOCYTE, MODIFIED PLATELET, AND METHODS RESPECTIVELY FOR PRODUCING SAID GENETICALLY MODIFIED MEGAKARYOCYTE AND SAID MODIFIED PLATELET Final Rejection KYOTO UNIVERSITY

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month